Silencing of SHCBP1 effectively promotes the inactivation of MAPK/ERK and PI3K/AKT/mTOR signaling pathways and reduces the expression of cyclin D1 in SS cells. The gene discussed is SHCBP1; the disease is synovial sarcoma.